H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on several compelling factors. Arcellx Inc’s anito-cel therapy has demonstrated promising clinical results in the treatment of relapsed or refractory multiple myeloma, with a high overall response rate and a significant complete response rate. The absence of delayed neurotoxicities in a substantial patient cohort further enhances its safety profile, distinguishing it from competitor therapies.
Additionally, the strategic partnership with Kite Pharma provides Arcellx with a strong manufacturing and commercialization advantage, ensuring efficient product turnaround times. The ongoing expansion of the ARC-SparX program and the initiation of a Phase 1 study for myasthenia gravis highlight the company’s commitment to broadening its therapeutic applications. These factors collectively support the Buy rating, positioning anito-cel as a potentially best-in-class BCMA CAR-T therapy with a commercial launch anticipated in 2026.
Bodnar covers the Healthcare sector, focusing on stocks such as AnaptysBio, Agenus, and NovoCure. According to TipRanks, Bodnar has an average return of -4.0% and a 26.69% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $115.00 price target.